Glucagon Regulation of Energy Expenditure
Open accessThe DOI matches its Crossref record; 93 of the 93 references it cites were found in a registry or an index.
Abstract
Glucagon’s ability to increase energy expenditure has been known for more than 60 years, yet the mechanisms underlining glucagon’s thermogenic effect still remain largely elusive. Over the last years, significant efforts were directed to unravel the physiological and cellular underpinnings of how glucagon regulates energy expenditure. In this review, we summarize the current knowledge on how glucagon regulates systems metabolism with a special emphasis on its acute and chronic thermogenic effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Unimolecular co-agonists of GLP-1R and the glucagon receptor (GcgR) were the first to emerge, seeking to leverage the anorectic and anti-diabetic effects of GLP-1 with the ability of Gcg to increase energy expenditure [[17], [18], [19]]”
From Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice (2022) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In animal models, glucagon stimulates energy expenditure through activation of brown adipose tissue [68], although the significance of this effect has not been confirmed by human data [69].”
From New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes—Beyond and within GLP-1 Receptor Agonists (2024) · cites this paper as [68]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Beyond the role of glucagon in glucose homeostasis, there are additional metabolic effects; these include increasing satiety and reducing food intake, as well as effects on lipid homeostasis and the increase of energy expenditure [8,9].”
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“germline Gipr-deficient mice are protected from diet-induced obesity103”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [103]
Experimental — accuracy not yet measuredIn the citing paper
“Glucagon (GCG) is a 29 amino acid peptide secreted by pancreatic α cells when blood glucose levels are low. Its ability to increase energy expenditure has been known for over 60 years (125).”
From GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach (2023) · cites this paper as [125]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Brown Adipose Tissue: Function and Physiological Significance
CANNON, B., & NEDERGAARD, J. (2004) · Physiological Reviews · doi:10.1152/physrev.00015.2003 · Cited by 6,433
Identification and Importance of Brown Adipose Tissue in Adult Humans
Cypess, A. M., Lehman, S., Williams, G., Tal, I., Rodman, D., Goldfine, A. B., Kuo, F. C., Palmer, E. L., Tseng, Y.-H., Doria, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810780 · Cited by 4,399
Activation of Human Brown Adipose Tissue by a β3-Adrenergic Receptor Agonist
Cypess, A. M., Weiner, L. S., Roberts-Toler, C., Elía, E. F., Kessler, S. H., Kahn, P. A., English, J., Chatman, K., Trauger, S. A., Doria, A., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2014.12.009 · Cited by 1,027
Mechanism of Fatty-Acid-Dependent UCP1 Uncoupling in Brown Fat Mitochondria
Fedorenko, A., Lishko, P. V., & Kirichok, Y. (2012) · Cell · doi:10.1016/j.cell.2012.09.010 · Cited by 968 · cited 1×
“UCP1 uncouples oxidative phosphorylation from ATP synthesis with the result that energy form substrate oxidation is released as heat [48,49].”
BackgroundUnderstanding the Physiology of FGF21
Fisher, F. M., & Maratos-Flier, E. (2016) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021115-105339 · Cited by 912 · cited 2×
“In the liver, glucagon stimulates the synthesis and release of fibroblast growth factor 21 (FGF21) [34,76], a circulating peptide hormone that regulates energy homeostasis [77,78] and is primarily derived from the liver [35,79] (Figure 2).”
BackgroundGlucagon and regulation of glucose metabolism
Jiang, G., & Zhang, B. B. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00492.2002 · Cited by 905
A guide to analysis of mouse energy metabolism
Tschöp, M. H., Speakman, J. R., Arch, J. R. S., Auwerx, J., Brüning, J. C., Chan, L., Eckel, R. H., Farese, R. V., Galgani, J. E., Hambly, C., et al. (2012) · Nature Methods · doi:10.1038/nmeth.1806 · Cited by 813
Self-citationA new glucagon and GLP-1 co-agonist eliminates obesity in rodents
Day, J. W., Ottaway, N., Patterson, J. T., Gelfanov, V., Smiley, D., Gidda, J., Findeisen, H., Bruemmer, D., Drucker, D. J., Chaudhary, N., et al. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.209 · Cited by 641
Self-citationThe essential role of glucagon in the pathogenesis of diabetes mellitus
Unger, R., & Orci, L. (1975) · The Lancet · doi:10.1016/s0140-6736(75)92375-2 · Cited by 599
Circulating FGF21 Is Liver Derived and Enhances Glucose Uptake During Refeeding and Overfeeding
Markan, K. R., Naber, M. C., Ameka, M. K., Anderegg, M. D., Mangelsdorf, D. J., Kliewer, S. A., Mohammadi, M., & Potthoff, M. J. (2014) · Diabetes · doi:10.2337/db14-0595 · Cited by 590 · cited 2×
“In the liver, glucagon stimulates the synthesis and release of fibroblast growth factor 21 (FGF21) [34,76], a circulating peptide hormone that regulates energy homeostasis [77,78] and is primarily derived from the liver [35,79] (Figure 2).”
Background
Cited by
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M. L. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2301972 · Cited by 1,174
Anti-obesity drug discovery: advances and challenges
Müller, T. D., Blüher, M., Tschöp, M. H., & DiMarchi, R. D. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00337-8 · Cited by 1,021
Self-citationRosenstock, J., Frias, J., Jastreboff, A. M., Du, Y., Lou, J., Gurbuz, S., Thomas, M. K., Hartman, M. L., Haupt, A., Milicevic, Z., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01053-x · Cited by 423
Sanyal, A. J., Kaplan, L. M., Frias, J. P., Brouwers, B., Wu, Q., Thomas, M. K., Harris, C., Schloot, N. C., Du, Y., Mather, K. J., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03018-2 · Cited by 315
Coskun, T., Urva, S., Roell, W. C., Qu, H., Loghin, C., Moyers, J. S., O’Farrell, L. S., Briere, D. A., Sloop, K. W., Thomas, M. K., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.07.013 · Cited by 316
Mechanisms driving the immunoregulatory function of cancer cells
van Weverwijk, A., & de Visser, K. E. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00544-4 · Cited by 272
GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach
Wang, J.-Y., Wang, Q.-W., Yang, X.-Y., Yang, W., Li, D.-R., Jin, J.-Y., Zhang, H.-C., & Zhang, X.-F. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1085799 · Cited by 248
Incretins (GLP-1 receptor agonists and dual/triple agonists) and the liver
Newsome, P. N., & Ambery, P. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.07.033 · Cited by 211
Harrison, S. A., Browne, S. K., Suschak, J. J., Tomah, S., Gutierrez, J. A., Yang, J., Roberts, M. S., & Harris, M. S. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2024.07.006 · Cited by 176
Bossart, M., Wagner, M., Elvert, R., Evers, A., Hübschle, T., Kloeckener, T., Lorenz, K., Moessinger, C., Eriksson, O., Velikyan, I., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2021.12.005 · Cited by 179
Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)
Do, A., Zahrawi, F., & Mehal, W. Z. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01084-2 · Cited by 169
Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice
Knerr, P. J., Mowery, S. A., Douros, J. D., Premdjee, B., Hjøllund, K. R., He, Y., Kruse Hansen, A. M., Olsen, A. K., Perez-Tilve, D., DiMarchi, R. D., et al. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101533 · Cited by 152
Transforming obesity: The advancement of multi-receptor drugs
Kusminski, C. M., Perez-Tilve, D., Müller, T. D., DiMarchi, R. D., Tschöp, M. H., & Scherer, P. E. (2024) · Cell · doi:10.1016/j.cell.2024.06.003 · Cited by 126
Self-citationThe past, present, and future physiology and pharmacology of glucagon
Capozzi, M. E., D’Alessio, D. A., & Campbell, J. E. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.10.001 · Cited by 109
Glucose-dependent insulinotropic polypeptide (GIP)
Müller, T. D., Adriaenssens, A. E., Ahrén, B., Blüher, M., Birkenfeld, A. L., Campbell, J. E., Coghlan, M. P., D’Alessio, D. D., Deacon, C. F., DelPrato, S., et al. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102118 · Cited by 113
Self-citationTschöp, M., Nogueiras, R., & Ahrén, B. (2023) · Diabetologia · doi:10.1007/s00125-023-05929-0 · Cited by 92
“Therefore, it is accepted that glucagon may affect energy expenditure via BAT-independent mechanisms (for review see [60, 61]).”
BackgroundStriking the balance: GLP-1/glucagon co-agonism as a treatment strategy for obesity
Hope, D. C. D., Vincent, M. L., & Tan, T. M. M. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.735019 · Cited by 81
“Despite several postulated theories of glucagon induced energy expenditure, the mechanism is likely multi-faceted and the precise contribution to these facets remains uncertain (58).”
BackgroundThe molecular pharmacology of glucagon agonists in diabetes and obesity
Novikoff, A., & Müller, T. D. (2023) · Peptides · doi:10.1016/j.peptides.2023.171003 · Cited by 82
“treatment for metabolic syndrome, however its hyperglycemic liability has made practical implementation non-existent [102,161,3,30,85].”
InfluentialSelf-citationPancreatic α-cells – The unsung heroes in islet function
Wendt, A., & Eliasson, L. (2020) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2020.01.006 · Cited by 88
Neonatal exposure to a wild-derived microbiome protects mice against diet-induced obesity
Hild, B., Dreier, M. S., Oh, J. H., McCulloch, J. A., Badger, J. H., Guo, J., Thefaine, C. E., Umarova, R., Hall, K. D., Gavrilova, O., et al. (2021) · Nature Metabolism · doi:10.1038/s42255-021-00439-y · Cited by 68
When fat meets the gut—focus on intestinal lipid handling in metabolic health and disease
Wit, M., Viera, J. T., Strohmeyer, A., Klingenspor, M., Hankir, M. K., & Sumara, G. (2022) · EMBO Molecular Medicine · doi:10.15252/emmm.202114742 · Cited by 73
Farhadipour, M., & Depoortere, I. (2021) · Nutrients · doi:10.3390/nu13061839 · Cited by 75
Glucagon's Metabolic Action in Health and Disease
Zeigerer, A., Sekar, R., Kleinert, M., Nason, S., Habegger, K. M., & Müller, T. D. (2021) · Comprehensive Physiology · doi:10.1002/cphy.c200013 · Cited by 59
Self-citationHepatic glucagon action: beyond glucose mobilization
Kajani, S., Laker, R. C., Ratkova, E. L., Will, S., & Rhodes, C. J. (2024) · Physiological Reviews · doi:10.1152/physrev.00028.2023 · Cited by 72
Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss
Reiss, A. B., Gulkarov, S., Lau, R., Klek, S. P., Srivastava, A., Renna, H. A., & De Leon, J. (2025) · Biomolecules · doi:10.3390/biom15030408 · Cited by 58
“Newer anti-obesity medications are being developed that have promise for altering energy expenditure, although these are multi-receptor agonists involving binding both GLP-1 receptors and receptors such as glucagon which has been associated with increased energy expenditure [104].”
Gut Microbiota Mediates Lactobacillus rhamnosus GG Alleviation of Deoxynivalenol-Induced Anorexia
Bai, Y., Meng, Q., Wang, C., Ma, K., Li, J., Li, J., & Shan, A. (2023) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.2c08076 · Cited by 57
Sztanek, F., Tóth, L. I., Pető, A., Hernyák, M., Diószegi, Á., & Harangi, M. (2024) · Biomedicines · doi:10.3390/biomedicines12061320 · Cited by 47
“In animal models, glucagon stimulates energy expenditure through activation of brown adipose tissue [68], although the significance of this effect has not been confirmed by human data [69].”
BackgroundWinther, J. B., & Holst, J. J. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15693 · Cited by 47
Friedrichsen, M. H., Endahl, L., Kreiner, F. F., Goldwater, R., Kankam, M., Toubro, S., & Nygård, S. B. (2023) · Molecular Metabolism · doi:10.1016/j.molmet.2023.101801 · Cited by 46
“Beyond the role of glucagon in glucose homeostasis, there are additional metabolic effects; these include increasing satiety and reducing food intake, as well as effects on lipid homeostasis and the increase of energy expenditure [8,9].”
BackgroundIs Glucagon Receptor Activation the Thermogenic Solution for Treating Obesity?
Conceição-Furber, E., Coskun, T., Sloop, K. W., & Samms, R. J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.868037 · Cited by 48
Glucagon, from past to present: a century of intensive research and controversies
Scheen, A. J., & Lefèbvre, P. J. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00349-7 · Cited by 44
Aliakbarian, H., Bhutta, H. Y., Heshmati, K., Unes Kunju, S., Sheu, E. G., & Tavakkoli, A. (2020) · Obesity Surgery · doi:10.1007/s11695-020-04877-7 · Cited by 43
“Non-glycemic effects of glucagon include modulation of food intake and satiety, lipid homeostasis, insulin secretion, and energy expenditure [20].”
BackgroundJeon, E., Lee, K. Y., & Kim, K.-K. (2023) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes23032 · Cited by 39
Bi, B., Yin, Y., Zhao, Y., He, M., Song, H., Kong, L., & Gao, Y. (2023) · Aquaculture Reports · doi:10.1016/j.aqrep.2023.101468 · Cited by 39
Jiang, Y., Wu, L., Zhu, X., Bian, H., Gao, X., & Xia, M. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02092-2 · Cited by 50
Insights into incretin-based therapies for treatment of diabetic dyslipidemia
Stemmer, K., Finan, B., DiMarchi, R. D., Tschöp, M. H., & Müller, T. D. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.05.008 · Cited by 43
Self-citationSimonsen, L., Lau, J., Kruse, T., Guo, T., McGuire, J., Jeppesen, J. F., Niss, K., Sauerberg, P., Raun, K., & Dornonville de la Cour, C. (2022) · PLOS ONE · doi:10.1371/journal.pone.0264974 · Cited by 36
Hypoaminoacidemia underpins glucagon-mediated energy expenditure and weight loss
Hope, D. C. D., Hinds, C. E., Lopes, T., Vincent, M. L., Shrewsbury, J. V., Yu, A. T. C., Davies, I., Scott, R., Jones, B., Murphy, K. G., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100810 · Cited by 32
“Glucagon also plays an important role in the hepatic catabolism of lipids and amino acids,(2) pancreatic beta-cell insulin secretion,(3) regulation of food intake,(4,5) and energy expenditure.(6) Given its effect on hepatic glucose mobilization, it is counterintuitive that glucagon could be used as a component of anti…”
BackgroundMechanisms of action of incretin receptor based dual- and tri-agonists in pancreatic islets
Folli, F. B., Finzi, G., Manfrini, R., Galli, A., Casiraghi, F., Centofanti, L., Berra, C., Fiorina, P., Davalli, A. M., Rosa, S. L., et al. (2023) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00236.2023 · Cited by 35
De Block, C. E. M., Dirinck, E., Verhaegen, A., & Van Gaal, L. F. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14640 · Cited by 29
Unlocking the multifaceted roles of GLP-1: Physiological functions and therapeutic potential
AL-Noshokaty, T. M., Abdelhamid, R., Abdelmaksoud, N. M., Khaled, A., Hossam, M., Ahmed, R., Saber, T., Khaled, S., Elshaer, S. S., & Abulsoud, A. I. (2025) · Toxicology Reports · doi:10.1016/j.toxrep.2025.101895 · Cited by 30
“It has been known to increase energy expenditure for over 60 years [294].”
Jiang, Y., Zhu, H., & Gong, F. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16106 · Cited by 36
360-Degree Perspectives on Obesity
Cuciureanu, M. D., Caratașu, C.-C., Gabrielian, L., Frăsinariu, O. E., Checheriță, L. E., Trandafir, L. M., Stanciu, G. D., Szilagyi, A., Pogonea, I., Bordeianu, G., et al. (2023) · Medicina · doi:10.3390/medicina59061119 · Cited by 37
Jalleh, R. J., Talley, N. J., Horowitz, M., & Nauck, M. A. (2026) · Journal of Clinical Investigation · doi:10.1172/jci194740 · Cited by 40
Chen, J., Li, L., Hu, X.-R., Wei, F., & Ma, S. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.590477 · Cited by 33
Perspectives in weight control in diabetes - survodutide
Klein, T., Augustin, R., & Hennige, A. M. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110779 · Cited by 25
Revisiting Resting Metabolic Rate: What is the Relation to Weight Fluctuations?
Argyrakopoulou, G., Fountouli, N., Dalamaga, Μ., & Kokkinos, A. D. (2023) · Current Obesity Reports · doi:10.1007/s13679-023-00528-x · Cited by 28
Sympathetic Innervation of White Adipose Tissue: to Beige or Not to Beige?
Münzberg, H., Floyd, Z. E., & Chang, J. S. (2021) · Physiology · doi:10.1152/physiol.00038.2020 · Cited by 23
Muzurović, E. M., Katsiki, N., Volčanšek, Š., Plescia, F., Rizzo, M., & Mantzoros, C. S. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156494 · Cited by 25
Chrysavgis, L., Kazanas, S., Bafa, K., Rozani, S., Koloutsou, M. E., & Cholongitas, Ε. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073832 · Cited by 27
Yang, Y., Wang, T., Chen, J., Wu, X., Wu, L., Zhang, W., Luo, J. G., Xia, J., Meng, Z., & Liu, X. (2021) · Aquaculture · doi:10.1016/j.aquaculture.2021.737221 · Cited by 22
Physiological Appetite Regulation and Bariatric Surgery
Ramasamy, I. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13051347 · Cited by 27
Ion transport peptide regulates energy intake, expenditure, and metabolic homeostasis inDrosophila
Gáliková, M., & Klepsatel, P. (2022) · Genetics · doi:10.1093/genetics/iyac150 · Cited by 26
Li, W., Kirchner, T., Ho, G., Bonilla, F., D'Aquino, K., Littrell, J., Zhang, R., Jian, W., Qiu, X., Zheng, S., et al. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14173 · Cited by 20
“GCGR agonism's effects on hepatic FGF21 and bile acid secretion in mice is the primary mediator of glucagon's effects on energy expenditure, although the importance of these pathways in humans and of other organs remains to be elucidated.(53) As glucagon does cross the blood-brain barrier(54) and has been proposed to…”
BackgroundLiu, C., Li, C., Cai, X., Zou, Y., Mo, J., chen, B., Cai, Y., Han, T., Huang, W., Qian, H., et al. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.104492 · Cited by 20
Regulation of Hepatic Lipid and Glucose Metabolism by INSP3R1
Perry, R. J. (2022) · Diabetes · doi:10.2337/dbi22-0003 · Cited by 20
Pharmacological modulation of adaptive thermogenesis: new clues for obesity management?
Genchi, V. A., Palma, G., Sorice, G. P., D’Oria, R., Caccioppoli, C., Marrano, N., Biondi, G., Caruso, I., Cignarelli, A., Natalicchio, A., et al. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02125-0 · Cited by 23
Short-term effects of high-protein, lower-carbohydrate ultra-processed foods on human energy balance
Hägele, F. A., Herpich, C., Koop, J., Grübbel, J., Dörner, R., Fedde, S., Götze, O., Boirie, Y., Müller, M. J., Norman, K., et al. (2025) · Nature Metabolism · doi:10.1038/s42255-025-01247-4 · Cited by 23
Proglucagon-derived peptides: human physiology and therapeutic potential
Gasbjerg, L. S., Nielsen, C. K., Suppli, M. P., Grøndahl, M. F. G., Holst, J. J., Knop, F. K., Jeppesen, P. B., & Lund, A. (2025) · Physiological Reviews · doi:10.1152/physrev.00057.2024 · Cited by 22
Golubić, R., Kennet, J., Parker, V., Robertson, D. C., Luo, D., Hansen, L. B., Jermutus, L., Ambery, P., Ryaboshapkina, M., Surakala, M., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15579 · Cited by 21
Glucagon controls obesity-specific energy expenditure via persistent cAMP/PKA signaling
Long, F., Challa, T. D., Ding, L., Sharma, A. K., Wu, C., Ghosh, A., Noé, F., Horváth, C., Liebisch, G., Höring, M., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.06.011 · Cited by 17
Hope, D. C. D., & Tan, T. M.-M. (2023) · Peptides · doi:10.1016/j.peptides.2023.170962 · Cited by 16
Lyons, S. A., & Beaudry, J. L. (2023) · Endocrinology · doi:10.1210/endocr/bqad153 · Cited by 19
Poly-Agonist Pharmacotherapies for Metabolic Diseases: Hopes and New Challenges
Allard, C., Cota, D., & Quarta, C. (2023) · Drugs · doi:10.1007/s40265-023-01982-6 · Cited by 17
Glucagon augments the secretion of FGF21 and GDF15 in MASLD by indirect mechanisms
Richter, M. M., Kemp, I. M., Heebøll, S., Winther‐Sørensen, M., Kjeldsen, S. A. S., Jensen, N. J., Nybing, J. D., Linden, F. H., Høgh‐Schmidt, E., Boesen, M., et al. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155915 · Cited by 15
Forst, T. M., Block, C. E. M. D., Prato, S. D., Frías, J. P., Lautenbach, A., Ludvik, B. H., Marinez, M., Mathieu, C., Müller, T. D., & Schnell, O. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16247 · Cited by 15
Self-citationBrowne, S., Suschak, J. J., Tomah, S., Gutierrez, J. A., Yang, J., Georges, B., Roberts, M. S., & Harris, M. S. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101483 · Cited by 18
Adipose Tissue, at the Core of the Action of Incretin and Glucagon-Based Anti-Obesity Drugs
Villarroya, F., Peyrou, M., & Giralt, M. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00660-w · Cited by 15
Friedrichsen, M., Endahl, L., Kreiner, F. F., Goldwater, R., Kankam, M., Toubro, S., & Nygård, S. B. (2022) · medRxiv · doi:10.1101/2022.06.02.22275920 · Cited by 14
A tumor-secreted protein utilizes glucagon release to cause host wasting
Ding, G., Li, Y., Chen, C., Tan, K., Deng, Y., Pang, H., Wang, Z., Dang, P., Wu, X., Rushworth, E., et al. (2025) · Cell Discovery · doi:10.1038/s41421-024-00762-0 · Cited by 14
Oral Treatment of Obesity by GLP-1 and Its Analogs
Holler, N., Ruseska, I., Schachner-Nedherer, A.-L., Zimmer, A., & Petschacher, C. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17121596 · Cited by 13
Perspectives in weight control in diabetes – SGLT2 inhibitors and GLP-1–glucagon dual agonism
Iqbal, N., Ambery, P., Logue, J., Mallappa, A., & Sjöström, C. D. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110669 · Cited by 14
The evolving landscape of obesity pharmacotherapy
Petersen, J., Finan, B., Johansen, V. B. I., Müller, T. D., & Clemmensen, C. (2026) · Nature Reviews Drug Discovery · doi:10.1038/s41573-026-01427-1 · Cited by 19
Self-citationA Mechanistic Rationale for Incretin-Based Therapeutics in the Management of Obesity
Samms, R. J., & Kusminski, C. M. (2024) · Annual Review of Physiology · doi:10.1146/annurev-physiol-022724-105443 · Cited by 12
Advances in obesity pharmacotherapy; learning from metabolic surgery and beyond
Tsilingiris, D., & Kokkinos, A. D. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155741 · Cited by 16
Chrysavgis, L., Mourelatou, N. G., Koloutsou, M. E., Rozani, S., & Cholongitas, Ε. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262412130 · Cited by 16
Ruocco, C., Malavazos, A. E., Ragni, M., Carruba, M. O., Valerio, A., Iacobellis, G., & Nisoli, E. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106892 · Cited by 11
Lasher, A. T., & Sun, L. Y. (2023) · Aging Cell · doi:10.1111/acel.13985 · Cited by 9
Stachteas, P., Nasoufidou, A., Karakasis, P., Koiliari, M., Karagiannidis, E., Koufakis, T., Fragakis, N., & Patoulias, D. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm39691 · Cited by 11
Research progress on the role of FGF21 in insulin resistance
Zhang, H., Zhu, R., Sun, Q., & Du, L. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1619462 · Cited by 16
Pancreatic Islet Cell Hormones: Secretion, Function, and Diabetes Therapy
Ma, J., Mao, L., Yang, L., Xie, Q., Fan, R., Lu, X., Huang, X., Tong, N., & Duan, Z. (2025) · MedComm · doi:10.1002/mco2.70359 · Cited by 20
Neff, G. W. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70148 · Cited by 13
Nuszkiewicz, J., Czuczejko, J., Dróżdż, W., Woźniak, A., Małkowski, B., & Szewczyk‐Golec, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043283 · Cited by 10
Gaffey, R. H., Takyi, A. K., & Shukla, A. P. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2377319 · Cited by 8
IUPHAR review: From foe to friend: Repurposing glucagon to treat obesity and type 2 diabetes
Elmendorf, A. J., Yousefian, M., Kim, I., Hardaway, J. A., Habegger, K. M., & Flak, J. N. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.108077 · Cited by 8
Self-citationDesigner GLP1 poly-agonist peptides in the management of diabesity
Statham, L., Pelling, M., Hanson, P., Kyrou, I., Randeva, H. S., & Barber, T. M. (2023) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2023.2204976 · Cited by 8
Huh, K. Y., Hwang, J. G., Shin, W., Baek, S. J., Choi, J., Lee, N., Cho, Y. M., & Lee, H. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14590 · Cited by 8
Lundemose, S. B., Ranjan, A. G., Nørgaard, O., Suvitaival, T., & Nørgaard, K. (2025) · Diabetes Care · doi:10.2337/dc25-0702 · Cited by 6
Hope, D. C. D., Ansari, S., Choudhury, S., Αλεξιάδου, Κ., Tabbakh, Y., Ilesanmi, I., Lazarus, K., Davies, I., Jimenez‐Pacheco, L., Yang, W. P., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15448 · Cited by 6
Proteomics profiles of blood glucose-related proteins involved in a Chinese longevity cohort
Zhang, R., Liu, F., Ye, S., Du, X., Ma, L., Cao, H., Wang, Z., & Li, C. (2022) · Clinical Proteomics · doi:10.1186/s12014-022-09382-w · Cited by 7
Glucagon-modified Liposomes Delivering Thyroid Hormone for Anti-obesity Therapy
Liu, J., Zhou, X., Feng, C., Zheng, W., Chen, P., Zhang, X., & Hou, P. (2023) · Archives of Medical Research · doi:10.1016/j.arcmed.2023.04.001 · Cited by 7
GLP‐1 Receptor Agonists and Weight Loss: A Critical Review of Mechanisms
Rutigliani, G., Cross, T.-W., de Jong, E., Glover, E. S., Mendoza, I. D., Adisa, M., Tomoo, K., Zhou, X., & Mattes, R. D. (2026) · Obesity Reviews · doi:10.1111/obr.70148 · Cited by 5
Innovative Glucagon-based Therapies for Obesity
Belay, K. E., Jemal, R. H., & Tuyizere, A. (2024) · Journal of the Endocrine Society · doi:10.1210/jendso/bvae197 · Cited by 8
Jiang, P., Zeng, Y., Yang, W. Y., Li, L., Zhou, L., Xiao, L., Li, Y., Gu, B., Li, X., Li, J., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116485 · Cited by 5
Ramsbacher, N. C. (2024) · Clinical Diabetes · doi:10.2337/cd24-0062 · Cited by 5
Moreno-Lopez, M., Louvet, I., Delalleau, N., Acosta-Montalvo, A., Thévenet, J., Pasquetti, G., Gmyr, V., Kerr-Conte, J. A., Pattou, F. N., Bonner, C., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16089 · Cited by 7
Wei, L. S., Khoo, M. I., Harikrishnan, R., Acar, Ü., Hosain, M. E., Azra, M. N., Kamarudin, A. S., Kian, L. K., Hadiana, & Wee, W. (2025) · Annals of Animal Science · doi:10.2478/aoas-2025-0038 · Cited by 6
Li, Q., Yang, Q., Han, J. D. J., Xiaohan, L. I. U., Fu, J., & Yin, J. (2022) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(22)60196-1 · Cited by 4
Exposure–response modeling for nausea incidence for cotadutide using a Markov modeling approach
Yu, H., Ueckert, S., Zhou, L., Cheng, J. Y., Robertson, D. C., Hansen, L. B., Flor, A., Parker, V., Hamrén, B., & Khan, A. A. (2024) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.13194 · Cited by 4
Zong, J., Wu, X., Huang, X., Yuan, L., Yuan, K., Zhang, Z., Jiang, M., Ping, Z., Cheong, L. Y., Xu, A., et al. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102133 · Cited by 7
Metadata
- Authors
- Kleinert, M., Sachs, S., Habegger, K. M., Hofmann, S. M., & Müller, T. D.
- Affiliations
- University of Copenhagen (DK)
- Helmholtz Munich (DE)
- University of Alabama at Birmingham (US)
- Corresponding author
- Müller, Timo D.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2019-10-30
- Volume
- 20
- Issue
- 21
- Pages
- 5407
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC6862306
- OpenAlex
- W2982363774
- Cited by
- 147
- References
- 93
- Citations by year
- 2026: 19 · 2025: 29 · 2024: 27 · 2023: 33 · 2022: 20 · 2021: 12 · 2020: 7
- FWCI
- 1.16
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion, other-oa)
- Site cant be reached (submittedVersion, cc-by)
- PuSH - Publication Server of Helmholtz Zentrum München (submittedVersion, cc-by)
- Funders
- Sanofi
- Deutsche Forschungsgemeinschaft (TRR- 152, SFB/TRR152, SFB TRR 152/2)
- Lundbeckfonden (R288-2018-78)
- Novo Nordisk
- Servier
- National Institutes of Health
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK112934, P30DK056336, P30DK079626)
- Topics
- Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- glucagon, energy expenditure, thermogenesis, thermogenic effect, cellular mechanisms
- MeSH terms
- Animals, Energy Metabolism, Glucagon, Humans, Thermogenesis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.